nach oben

Erschienen in:

01.07.2012 | Laboratory Investigation

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

verfasst von: Shingo Takano, Yukinari Kato, Tetsuya Yamamoto, Mika Kato Kaneko, Eiichi Ishikawa, Yuta Tsujimoto, Masahide Matsuda, Kei Nakai, Ryo Yanagiya, Shunpei Morita, Koji Tsuboi, Akira Matsumura

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations, which are early and frequent genetic alterations in astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, are specific to arginine 132 (R132). Recently, we established monoclonal antibodies (mAbs) against IDH1 mutations: anti-IDH1-R132H and anti-IDH1-R132S. However, the importance of immunohistochemistry using the combination of those mAbs has not been elucidated. For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1). IDH1 mutation was detected, respectively, in 9.7%, 63.6%, 51.7%, and 77.8% of primary grade IV, secondary grade IV, grade III, and grade II gliomas. For each grade of glioma, prognostic factors for progression-free survival and overall survival were evaluated using clinical and pathological parameters in addition to IDH1 immunohistochemistry. IDH1 mutation, p53 overexpression, and internexin expression, as evaluated using immunohistochemistry with clinical parameters such as degree of surgical removal and preoperative Karnofsky Performance Status (KPS), might be of greater prognostic significance than histological grading alone in grade III as well as IDH1 mutation in grade IV gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCrossRef

Sonoda Y, Kumabe T, Nakamura T, Kanamori M, Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998PubMedCrossRef

Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153PubMedCrossRef

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744PubMedCrossRef

Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265PubMedCrossRef

Williams SC, Karajannis MA, Chiriboga L, Golfin JG, von Deimling A, Zagzag D (2011) R132H mutantion of isocitrate dehydrogenase-1 is not efficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:274–281CrossRef

Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik LH, Figarella-Branger D (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105(3):591–600

Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1^R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547–551PubMedCrossRef

Kaneko M, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation. Biochem Biophys Res Commun 406:608–613PubMedCrossRef

10.

Capper D, Zentqraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601PubMedCrossRef

11.

Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Yamazaki K, Kato Y, Matsumura A (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123PubMedCrossRef

12.

Ducray F, Criniere E, Idbaih A, Mokhtari K, Maric Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thilet J, Hoang-Xuan K, Delattre JY, Sanson M (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161PubMedCrossRef

13.

Ducray F, Mokhtari K, Crinière E, Idbaih A, Marie Y, Dehais C, Paris S, Carpentier C, Dieme MJ, Adam C, Hoang-Xuan K, Duyckaerts C, Delattre JY, Sanson M (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808PubMedCrossRef

14.

Durand K, Guillaudeau A, Pommepuy I, Mesturoux L, Chaunavel A, Gadeaud E, Porcheron M, Moreau JJ, Labrousse F (2011) Alpha-internexin in gliomas, relationship with histological type and 1p, 19q, 10p and 10q status. J Clin Pathol 64:793–801PubMedCrossRef

15.

Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoom M, Wesseling P, Hoang-Xuan K, van den Bent M, sanson M (2011) Alpha-internexin expression predicts outcome IN anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 117:3014–3026PubMedCrossRef

16.

Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA (2011) Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70:715–723PubMedCrossRef

17.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358PubMedCrossRef

18.

Christman M, Naegel G, Hom S, Krhan U, Wiewroft D, Sommer C, Kaima B (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127:2106–2118CrossRef

19.

Momota H, narita Y, Matsushita Y, Miyakita Y, Shibui S (2010) p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 27:95–101PubMedCrossRef

20.

Pardo FS, Hsu DW, Zeheb R, Efird JT, Okurief PG, Malkin DM (2004) Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 91:1678–1686PubMed

21.

Kloosterhof NK, Bralte LB, Dubbink HJ, French PJ, van den Bent M (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12:83–91PubMedCrossRef

22.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisseller B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154PubMedCrossRef

23.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoom MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16:1597–1604PubMedCrossRef

24.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenerger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRef

25.

Gupta R, Webb-Myers R, Flanagan S, Buckland ME (2011) Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 64:835–844 (July 12 [Epub ahead of print])PubMedCrossRef

26.

Capper D, Weibert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254PubMedCrossRef

27.

Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in astrocytomas predict survival but not response to temozolomide. Neurology 73:1792–1795PubMedCrossRef

28.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2011) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452–460PubMedCrossRef

29.

Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawaski R, Watanabe T, de Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse glioma. Am J Pathol 177:2708–2714PubMedCrossRef

30.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guilevin R, Laffaire J, Paris S, Boisselier B, Idbah A, Laigle-Donadey F, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozlomide in low-grade gliomas. Neurology 75:1560–1566PubMedCrossRef

31.

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB, European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group, European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRef

32.

Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhatari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiological and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729PubMedCrossRef

33.

Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12PubMedCrossRef

34.

Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathway in the evolution of gliomas. Cancer Sci 100:2235–2241PubMedCrossRef

35.

Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2011) Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol 49:88–93PubMed

36.

Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD (2002) p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 51:1246–1254PubMedCrossRef

37.

Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226(1):7–16PubMedCrossRef

38.

Precusser M, Charles JR, Felsberg J, Reifenberger G, Hanou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heizl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methytransferase (MGMT) immunohistochemistry in glioblastoma multiforme observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520–532

39.

Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastoma. Neurosurgery 65:866–875PubMedCrossRef

Titel: Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
verfasst von: Shingo Takano
Yukinari Kato
Tetsuya Yamamoto
Mika Kato Kaneko
Eiichi Ishikawa
Yuta Tsujimoto
Masahide Matsuda
Kei Nakai
Ryo Yanagiya
Shunpei Morita
Koji Tsuboi
Akira Matsumura
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0837-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas

Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression

Stereotactic radiosurgery for patients with recurrent intracranial ependymomas

Erratum to: Development of a novel animal model to differentiate radiation necrosis from tumor recurrence

FABP4 is a candidate marker of cerebellar liponeurocytomas